Literature DB >> 24599780

The impact of peri-operative anti-TNF treatment on anastomosis-related complications in Crohn's disease patients. A critical review.

Ioannis Papaconstantinou1, Christos Zeglinas, Maria Gazouli, Konstantinos Nastos, Anneza Yiallourou, Apostolos Papalois, Charalambos Tzathas.   

Abstract

INTRODUCTION: Tumor necrosis factor (TNF)α is a cytokine exerting pleiotropic effects on critical cell functions and, most importantly, is the main regulator of pro-inflammatory cytokine production and a key player in the pathophysiology of numerous autoimmune diseases, including Crohn's disease.
METHODS: TNFα became a therapeutic target and TNFα blocking agents are currently used in the treatment of inflammatory diseases. Beyond the therapeutic benefits deriving from TNFα neutralization, amendments in the cellular functions of the immune system may as well induce potent immunosuppressive effects. An attenuated immune response may compromise the intestinal healing ability, thus leading to weaker anastomosis and increased risk of anastomotic leak and septic complications.
RESULTS: This hypothesis raises great concerns about the safety of perioperative administration of anti-TNF and has been the endpoint of numerous studies.
CONCLUSION: The aim of this review is to critically evaluate the evidence regarding the role of TNFα in anastomosis related complications after abdominal surgery in Crohn's disease patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24599780     DOI: 10.1007/s11605-014-2487-3

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  34 in total

1.  Methodological index for non-randomized studies (minors): development and validation of a new instrument.

Authors:  Karem Slim; Emile Nini; Damien Forestier; Fabrice Kwiatkowski; Yves Panis; Jacques Chipponi
Journal:  ANZ J Surg       Date:  2003-09       Impact factor: 1.872

2.  The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study.

Authors:  L Marchal; G D'Haens; G Van Assche; S Vermeire; M Noman; M Ferrante; M Hiele; M Bueno De Mesquita; A D'Hoore; F Penninckx; P Rutgeerts
Journal:  Aliment Pharmacol Ther       Date:  2004-04-01       Impact factor: 8.171

3.  A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease.

Authors:  S E Plevy; C J Landers; J Prehn; N M Carramanzana; R L Deem; D Shealy; S R Targan
Journal:  J Immunol       Date:  1997-12-15       Impact factor: 5.422

4.  Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2.

Authors:  Arianne L Theiss; James G Simmons; Christian Jobin; P Kay Lund
Journal:  J Biol Chem       Date:  2005-09-01       Impact factor: 5.157

Review 5.  Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis.

Authors:  Uri Kopylov; Shomron Ben-Horin; Oded Zmora; Rami Eliakim; Lior H Katz
Journal:  Inflamm Bowel Dis       Date:  2012-03-29       Impact factor: 5.325

6.  Surgical resection in Crohn's disease: is immunosuppressive medication associated with higher postoperative infection rates?

Authors:  J Canedo; S-H Lee; R Pinto; S Murad-Regadas; L Rosen; S D Wexner
Journal:  Colorectal Dis       Date:  2011-11       Impact factor: 3.788

7.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

8.  Effect of perioperative immunosuppressive medication on early outcome in Crohn's disease patients.

Authors:  Adrian A Indar; Tonia M Young-Fadok; Jacques Heppell; Jonathan E Efron
Journal:  World J Surg       Date:  2009-05       Impact factor: 3.352

Review 9.  Yin and yang in cytokine regulation of corneal wound healing: roles of TNF-alpha.

Authors:  Shizuya Saika
Journal:  Cornea       Date:  2007-10       Impact factor: 2.651

10.  Infliximab pharmacokinetics in inflammatory bowel disease patients.

Authors:  David Ternant; Alexandre Aubourg; Charlotte Magdelaine-Beuzelin; Danielle Degenne; Hervé Watier; Laurence Picon; Gilles Paintaud
Journal:  Ther Drug Monit       Date:  2008-08       Impact factor: 3.681

View more
  11 in total

1.  Immunosuppressed Patients with Crohn's Disease Are at Increased Risk of Postoperative Complications: Results from the ACS-NSQIP Database.

Authors:  Maria Abou Khalil; Jad Abou-Khalil; Jennifer Motter; Carol-Ann Vasilevsky; Nancy Morin; Gabriela Ghitulescu; Marylise Boutros
Journal:  J Gastrointest Surg       Date:  2019-03-18       Impact factor: 3.452

2.  Effect of Anti-TNF Agents on Postoperative Outcomes in Inflammatory Bowel Disease Patients: a Single Institution Experience.

Authors:  Chaya Shwaartz; Adam C Fields; Maximiliano Sobrero; Brian D Cohen; Celia M Divino
Journal:  J Gastrointest Surg       Date:  2016-07-12       Impact factor: 3.452

Review 3.  The Role of Temporary Fecal Diversion.

Authors:  Amy L Lightner; John H Pemberton
Journal:  Clin Colon Rectal Surg       Date:  2017-05-22

4.  Risk factors for postoperative complications after elective ileocolic resection for Crohn's disease: a retrospective study.

Authors:  Antonios Gklavas; Aikaterini Poulaki; Dionysios Dellaportas; Ioannis Papaconstantinou
Journal:  Ann Gastroenterol       Date:  2020-09-16

5.  Infliximab Does Not Promote the Presence of Collagenolytic Bacteria in a Mouse Model of Colorectal Anastomosis.

Authors:  Sara Gaines; Sanjiv Hyoju; Ashley J Williamson; Jasper B van Praagh; Olga Zaborina; David T Rubin; John C Alverdy; Benjamin D Shogan; Neil Hyman
Journal:  J Gastrointest Surg       Date:  2020-01-02       Impact factor: 3.452

Review 6.  Biologics and surgical outcomes in Crohn's disease: is there a direct relationship?

Authors:  Abel Botelho Quaresma; Takayuki Yamamoto; Paulo Gustavo Kotze
Journal:  Therap Adv Gastroenterol       Date:  2020-07-16       Impact factor: 4.409

7.  The Attenuation of Chronic Ulcerative Colitis by (R)-salbutamol in Repeated DSS-Induced Mice.

Authors:  Liangjun Deng; Haihua Guo; Shanping Wang; Xiaoming Liu; Yue Lin; Rui Zhang; Wen Tan
Journal:  Oxid Med Cell Longev       Date:  2022-02-07       Impact factor: 6.543

Review 8.  A review on chemical-induced inflammatory bowel disease models in rodents.

Authors:  Puneet Kaur Randhawa; Kavinder Singh; Nirmal Singh; Amteshwar Singh Jaggi
Journal:  Korean J Physiol Pharmacol       Date:  2014-08-13       Impact factor: 2.016

9.  Perioperative use of immunosuppressive medications in patients with Crohn's disease in the new "biological era".

Authors:  Amy L Lightner; Bo Shen
Journal:  Gastroenterol Rep (Oxf)       Date:  2017-04-07

Review 10.  Helicobacter pylori infection and esophageal adenocarcinoma: a review and a personal view.

Authors:  Stergios A Polyzos; Christos Zeglinas; Fotini Artemaki; Michael Doulberis; Evangelos Kazakos; Panagiotis Katsinelos; Jannis Kountouras
Journal:  Ann Gastroenterol       Date:  2017-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.